Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination

Wouter W. van Willigen, Martine Bloemendal, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Rutger H.T. Koonstra, Astrid A.M. van der Veld, John B. A. G. Haanen, Steve Boudewijns, Gerty Schreibelt, Winald R. Gerritsen, I. Jolanda M. de Vries, and Kalijn F. Bol

Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands; Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands; Department of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands; Department of Internal Medicine, Hospital Rijnstate, Arnhem, The Netherlands; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Medical Oncology, Bravis Hospital, Roosendaal, The Netherlands

ABSTRACT

Vaccination with autologous dendritic cells (DC) loaded ex vivo with melanoma-associated antigens is currently being tested as an adjuvant treatment modality for resected locoregional metastatic (stage III) melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical efficacy of concurrent or sequential immune checkpoint inhibition (ICI). The purpose of this study was to determine the efficacy of ICI administered following recurrent disease during, or after, adjuvant DC vaccination. To this end, we retrospectively analyzed clinical responses of 51 melanoma patients with either irresectable stage III or stage IV disease treated with first- or second-line ICI following recurrence on adjuvant DC vaccination. Patients were analyzed according to the form of ICI administered: PD-1 inhibition monotherapy (nivolumab or pembrolizumab), ipilimumab monotherapy or combined treatment with ipilimumab and nivolumab. Treatment with first- or second-line PD-1 inhibition monotherapy after recurrence on adjuvant DC vaccination resulted in a response rate of 52%. In patients treated with ipilimumab monotherapy and ipilimumab-nivolumab response rates were 35% and 75%, respectively. In conclusion, ICI is effective in melanoma patients with recurrent disease on adjuvant DC vaccination.

Introduction

Melanoma is a highly malignant melanocyte-derived neoplasm. Surgical resection with curative intent is the primary treatment modality for local and locoregional disease. However, with advancing stage, surgical cure becomes increasing unlikely with 5-year melanoma-specific survival rates ranging from 93% (stage IIIA) to 32% (stage IIID) although the prognosis of melanoma patients having locoregional disease has likely improved since the advent of adjuvant systemic therapy. In distant metastatic disease (stage IV melanoma), surgery has limited value and therapy mainly consists of systemic treatment with immune checkpoint inhibition (ICI) and targeted therapy.

ICI consists of monoclonal antibodies intended to enhance the cancer-eradicating capacity of the immune system by restraining the immune-inhibiting function of CTLA-4 (ipilimumab) and PD-1 (nivolumab and pembrolizumab). Stage IV melanoma patients can be treated with either antibody as monotherapy or with the combination of ipilimumab and nivolumab. For resected stage III melanoma patients, all of the previous-mentioned agents are approved as monotherapy, with PD-1 inhibition outperforming ipilimumab. Besides ICI, targeted therapy with combined BRAF inhibition and MEK inhibition (BRAF/MEKi) is approved for both the treatment of stage IV melanoma and the adjuvant treatment of stage III melanoma.

Over the past years, we extensively studied dendritic cell (DC) vaccination in both stage III and stage IV melanoma patients. DC vaccination involves the administration of autologous DC matured and loaded ex vivo with melanoma-associated antigens. DC vaccination aims to eradicate melanoma cells by activating melanoma-specific T-cells in vivo. In stage III patients, adjuvant DC vaccination protocols induced functional melanoma-specific T-cell responses in 71% of patients, compared to 23% in metastatic melanoma patients. When retrospectively compared to matched historical controls, adjuvant DC vaccination improved overall survival (OS). Although clinical response following DC vaccination has been observed in some stage IV patients, DC vaccination is considerably less effective in these patients compared to ICI and BRAF/MEKi. Therefore, in melanoma, we focus on the adjuvant application of DC vaccination, with a phase III trial currently ongoing (NCT02993315).

The high rate of immune induction following adjuvant DC vaccination offers unique possibilities for its positioning...
within the systemic treatment landscape of melanoma. Based on its mechanism of action, DC vaccination might potentiate the clinical efficacy of concurrent or sequential ICI treatment. The potential synergy between ICI and DC vaccination can be explained using the cancer-immunity cycle proposed by Chen and Mellman.26 This cycle illustrates the steps cytotoxic T-cells have to complete before cancer cells can successfully be eradicated. Failure to complete any of these processes results in the incomplete clearance of malignant cells. DC vaccination aims to improve the activation of naive T-cells, whilst ICI is intended to reduce T-cell inhibition. Therefore, both modalities may be complementary as they act on different steps of the cancer-immunity cycle.27

In this study, we explore the clinical outcome of patients treated with PD-1 inhibition monotherapy or ipilimumab-nivolumab following recurrence on adjuvant DC vaccination for completely resected stage III disease. In addition, we present updated data on ipilimumab monotherapy following recurrence on adjuvant DC vaccination.

Materials and methods

Patients and treatment

We retrospectively analyzed patients treated with ICI (nivolumab, pembrolizumab or ipilimumab monotherapy, or ipilimumab-nivolumab) for recurrent disease after receiving DC vaccination for the adjuvant treatment of resected stage III cutaneous melanoma. All patients were treated with adjuvant DC vaccination between August 2004 and August 2018 in different study protocols (supplementary table 1). Briefly, vaccines consisted of autologous monocyte-derived or naturally circulating DC loaded with melanoma antigens. Patients were treated with three biweekly DC vaccinations (one cycle), with two additional cycles at six-month intervals in the absence of recurrent disease. Patients were evaluated every 3–6 months by medical history and physical examination. Imaging was performed at the discretion of the physician, except in the MIND-DC trial (NCT02993315) in which CT scanning was performed consistently during the follow-up visits. All DC vaccination studies were approved by the appropriate ethical review boards and written informed consent was obtained from all patients. After disease recurrence on adjuvant DC vaccination, patients who received ICI as first- or second-line treatment for metastatic disease were evaluated for response, progression-free survival (PFS) and OS. Patients started ICI between October 2008 and December 2018. Later patients were excluded due to short follow-up at the time of analysis (March 2019). Patients were analyzed according to the type of ICI administered: PD-1 inhibition monotherapy, ipilimumab monotherapy or ipilimumab-nivolumab. Ipilimumab monotherapy was administered at a dose of 3 mg/kg for four cycles to all patients except one. This patient received ipilimumab monotherapy in a compassionate use program at a dose of 10 mg/kg for four cycles followed by 10 mg/kg every 12 weeks as maintenance therapy. Patients treated with PD-1 inhibition monotherapy received pembrolizumab 2 mg/kg every 3 weeks, nivolumab 3 mg/kg every 2 weeks or nivolumab 480 mg fixed dose every 4 weeks. All patients treated with ipilimumab-nivolumab received nivolumab at a dose of 1 mg/kg plus ipilimumab at a dose of 3 mg/kg every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg/kg every 2 weeks. Patients were treated until scheduled therapy end, progressive disease (PD), unacceptable toxicity or a treatment pause in the setting of disease response.

Immunological monitoring

In the DC vaccination trials, the immunological response was monitored after each DC vaccination cycle except in the MIND-DC trial in which immunological response was determined only following the first cycle. Immunological response was tested using delayed-type hypersensitivity (DTH) skin tests as described previously.14 Briefly, patients received intradermal injections of DC loaded with melanoma antigens. After 48 h, 6 mm punch biopsies were taken from the injected skin. In these biopsies, skin-test infiltrating lymphocytes (SKIL) were analyzed for antigen-specific T-cells using multimeric-MHC complexes containing the relevant antigen epitopes. Furthermore, the presence of functional T-cells in the SKIL was assessed by measuring the interferon (IFN)-γ production upon stimulation with melanoma-associated antigen (supplementary figure 1). Patients with functional T-cells producing IFN-γ and/or having antigen-specific T-cells in at least one of the DTH skin tests were considered to have a melanoma-specific immunological response.

Response evaluation

Patients underwent radiological evaluations during ICI using CT which were planned every 3 months with the possibility of extended intervals when patients experienced durable stable disease, partial (PR) or complete response (CR). Responses were assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.28 Most patients (86%) were evaluated for the presence of cerebral metastases using MRI or CT prior to ICI start. The response rate is calculated as the portion of patients experiencing a PR or CR. The disease control rate is defined as the portion of patients experiencing stable disease, PR or CR.

Statistical analysis

Survival data were calculated using the Kaplan–Meier method. OS is defined as the time from the initiation of ICI until death from any cause. PFS is the time from the first administration of ICI until PD. Median follow-up time was calculated with the Kaplan–Meier method, using the date of ICI start to the date of last follow-up and censoring for death.29 Correlation between immunological outcome during DC vaccination and survival parameters on subsequent ICI
treatment was determined using a log-rank test. Correlation between immunological outcome during DC vaccination and clinical response was assessed using a Fisher’s Exact test. SPSS software version 25 (SPSS Inc., Chicago, IL) and GraphPad version 5.03 (GraphPad Software Inc., San Diego, CA) were used for statistical analysis.

**Results**

**Patient and treatment characteristics**

A total of 51 patients received ICI as first- and/or second-line treatment for unresectable stage III or stage IV melanoma after recurrence on adjuvant DC vaccination. Median recurrence-free survival on adjuvant DC vaccination was 7.9 months. All patients received at least one DC vaccine with 47 patients completing at least one cycle of three DC vaccines. As introduced before, patients were analyzed in three separate treatment groups (PD-1 inhibition monotherapy, ipilimumab monotherapy and ipilimumab-nivolumab) (Figure 1). Baseline characteristics of the patients in each treatment group are shown in Table 1.

**Clinical efficacy of ICI following recurrence on adjuvant DC vaccination**

Median follow-up time, from the first administration of ICI, was 10 months for patients treated with PD-1 inhibition monotherapy, 66 months for patients treated with ipilimumab monotherapy and 13 months for patients to whom ipilimumab-nivolumab was given.

Response rates following ICI are shown in Table 2. The response rate in patients treated with first- or second-line PD-1 inhibition monotherapy was 52%. In the ipilimumab-nivolumab group, the highest response rate (75%) was observed following first- or second-line treatment. In patients treated with first- or second-line ipilimumab monotherapy, the lowest response rate was seen, 35%.

Kaplan–Meier curves depicting PFS and OS of patients receiving first- or second-line ICI in different treatment groups are shown in Figure 2. There were no significant differences found in PFS and OS between first- and second-line PD-1 inhibition monotherapy or first- and second-line ipilimumab monotherapy (data not shown). First- and second-line ipilimumab-nivolumab were not analyzed separately as only two patients received second-line ipilimumab-nivolumab.

PFS rates after 1 and 2 y were 53% and 34% for patients treated with PD-1 inhibition monotherapy, respectively. After 1 y, 37% of the patients treated with ipilimumab monotherapy were free of progression. The 2- and 5-y PFS rates following ipilimumab monotherapy were 37% and 31%, respectively. Following PD-1 inhibition monotherapy, 93% of patients were alive after 1 y, after 2 y this was 66%. One, 2- and 5-y OS rates for ipilimumab monotherapy were 73%, 50% and 39%, respectively. For patients treated with ipilimumab-nivolumab, 1-y PFS and OS rates were 50% and 66%, respectively, but follow-up in this treatment group is limited.

**Immunological response on DC vaccination and the subsequent clinical efficacy of ICI**

No correlation between the presence of a melanoma-specific immunological response after DC vaccination and PFS or OS after ICI treatment was found in any of the treatment groups (data not shown). Neither was a melanoma-specific immunological response during DC vaccination more prevalent in ICI-responding patients compared to patients not responding to ICI (supplementary figures 1 and 2).

**Discussion**

ICI following recurrence on adjuvant DC vaccination led to clinical benefit in a considerable portion of metastatic melanoma patients. Clinical response was observed in 52% of the patients treated with first- or second-line PD-1 inhibition monotherapy. In the ipilimumab monotherapy and the ipilimumab-nivolumab groups, 35% and 75% of patients responded to treatment, respectively.

Of the patients treated with PD-1 inhibition monotherapy, the majority had no cerebral metastases and a normal lactate dehydrogenase (LDH), both positive predictors for response and survival.30,31 This patient selection resulted from
treatment guidelines in the institutions were patients received ICI. According to these guidelines, patients lacking an elevated LDH, cerebral metastases, high tumor load and rapid disease progression should preferably be treated with PD-1 inhibition monotherapy instead of ipilimumab-nivolumab. When taking the favorable characteristics into account, the response rate of 52% of the PD-1 inhibition monotherapy cohort is similar to the 51% response rate reported in comparable patients (i.e. patients with a normal LDH and no active cerebral metastases) following nivolumab monotherapy. The observed response rate of 35% in patients treated with ipilimumab monotherapy is higher than the response rates of 11–19% reported of ipilimumab monotherapy in melanoma patients without prior DC vaccination. However, the comparison between our cohort and the published data is complicated by differences in patient characteristics. In the published trials, the presence of active cerebral metastases was an exclusion criterion (with 5–11% of patients having treated cerebral metastases). In our cohort, 20% of patients had cerebral metastases of which 75% were treated. The portion of patients having an elevated LDH was slightly lower in our cohort (20%), compared to 33–39% in published trials. Lastly, in our cohort, a portion of patients received prior PD-1 inhibition monotherapy before ipilimumab monotherapy. As responses to ipilimumab monotherapy after progressive disease on PD-1 inhibition monotherapy are reported to be similar to first-line ipilimumab monotherapy, we regard the influence of prior PD-1 inhibition monotherapy on response rates to be limited.

All patients in our ipilimumab-nivolumab cohort had an elevated LDH, cerebral metastases and/or rapid disease progression before the start of ICI. Despite these unfavorable characteristics, our ipilimumab-nivolumab cohort showed a response rate of 75% which is higher than the 58% response rate described in literature. However, our results may be biased as our small cohort is prone to sampling errors, complicating extrapolation to larger numbers of patients.

Table 1. Patient baseline characteristics at the start of immune checkpoint inhibition.

|                                | PD-1 inhibition monotherapy after DC vaccination (n = 29) | Ipilimumab monotherapy after DC vaccination (n = 20) | Ipilimumab-nivolumab after DC vaccination (n = 8) |
|--------------------------------|----------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------|
| Age (mean)                     | 55 (37–74)                                               | 53 (24–69)                                          | 60 (43–78)                                       |
| Sex                            |                                                          |                                                     |                                                  |
| Male                           | 17 (59%)                                                 | 17 (85%)                                            | 8 (100%)                                         |
| Female                         | 12 (41%)                                                 | 3 (15%)                                             | 0                                                |
| Number of completed cycles of  |                                                          |                                                     |                                                  |
| DC vaccination                 |                                                          |                                                     |                                                  |
| 0 (1 or 2 vaccines)            | 2 (7%)                                                   | 0                                                   | 2 (25%)                                          |
| 1                              | 14 (48%)                                                 | 3 (15%)                                             | 4 (50%)                                          |
| 2                              | 6 (21%)                                                  | 6 (30%)                                             | 1 (13%)                                          |
| 3                              | 7 (24%)                                                  | 11 (55%)                                            | 1 (13%)                                          |
| Stage (AJCC 7th ed.) at start  |                                                          |                                                     |                                                  |
| of ICI                         |                                                          |                                                     |                                                  |
| Unresectable stage III         | 5 (17%)                                                  | 0                                                   | 0                                                |
| M1a                            | 5 (17%)                                                  | 3 (15%)                                             | 1 (13%)                                          |
| M1b                            | 8 (28%)                                                  | 5 (25%)                                             | 0                                                |
| M1c                            | 11 (38%)                                                 | 12 (60%)                                            | 7 (88%)                                          |
| B BRAF mutation                |                                                          |                                                     |                                                  |
| V600 mutation                  | 16 (55%)                                                 | 10 (50%)                                            | 6 (75%)                                          |
| No V600 mutation               | 13 (45%)                                                 | 5 (25%)                                             | 2 (25%)                                          |
| Unknown                        | 0                                                        | 5 (25%)                                             | 0                                                |
| Lactate dehydrogenase          |                                                          |                                                     |                                                  |
| ≤ULN                           | 26 (90%)                                                 | 16 (80%)                                            | 3 (38%)                                          |
| >ULN                           | 3 (10%)                                                  | 4 (20%)                                             | 5 (63%)                                          |
| Cerebral metastases            |                                                          |                                                     |                                                  |
| Yes                            | 0                                                        | 4 (20%)                                             | 2 (25%)                                          |
| No                             | 24 (83%)                                                 | 14 (70%)                                            | 6 (75%)                                          |
| Unknown                        | 5 (17%)                                                  | 2 (10%)                                             | 0                                                |
| Local treatment for cerebral   |                                                          |                                                     |                                                  |
| metastasesa                    |                                                          |                                                     |                                                  |
| No treatment                   | N/A                                                      | 0                                                   | 1 (50%)                                          |
| Surgery                        | N/A                                                      | 1 (25%)                                             | 0                                                |
| Radiotherapy                   | N/A                                                      | 3 (75%)                                             | 1 (50%)                                          |
| Line of treatment              |                                                          |                                                     |                                                  |
| First                          | 24 (83%)                                                 | 10 (50%)                                            | 6 (75%)                                          |
| Second                         | 5 (17%)                                                  | 10 (50%)                                            | 2 (25%)                                          |
| Prior systemic treatment       |                                                          |                                                     |                                                  |
| None                           | 24 (83%)                                                 | 10 (50%)                                            | 6 (75%)                                          |
| Dacarbazine                    | 0                                                        | 3 (15%)                                             | 0                                                |
| PD-1 inhibition monotherapy    | N/A                                                      | 3 (15%)                                             | 0                                                |
| BRAF/MEKi                      | 2 (7%)                                                   | 0                                                   | 2 (25%)                                          |
| BRAFi monotherapy              | 0                                                        | 4 (20%)                                             | 0                                                |
| Ipilimumab monotherapy         | 3 (10%)                                                  | N/A                                                 | 0                                                |

apercentage of patients having cerebral metastases.

Abbreviations: AJCC, American Joint Committee on Cancer; BRAF/MEKi, BRAF/MEK inhibition; BRAFi, BRAF inhibition; DC, dendritic cell; ICI, immune checkpoint inhibition; N/A, not applicable; ULN, upper limit of normal.
Clinical efficacy of immune checkpoint inhibition following dendritic cell vaccination.

Studies investigating whether DC vaccination has a role within the future treatment landscape of melanoma patients in case of recurrence.

First, all patients analyzed in this study were refractory to DC vaccination. Therefore, although melanoma-specific T cells could be detected after DC vaccination, the T cells might not have been susceptible for stimulation with ICI. Second, the response to the chosen target (melanoma-associated antigens) might be too weak to translate into clinical effect (possibly in contrast to neo-antigens). Third, it may be that our method of immunological monitoring does not capture the complete spectrum of immune induction following DC vaccination. Finally, our immunomonitoring method only conveys a snapshot of the T-cell status at the moment of testing, and may therefore not be representative of the T-cell status at the time of ICI.

Still, sequential DC vaccination potentially has synergy with ICI. Recent work by Linette et al. strengthens this idea as it implicates immunological ignorance of clonal neoantigens as the basis for ineffective T-cell immunity and suggested to employ DC vaccination as an adjunct to ICI. Our group has previously demonstrated that treatment with ipilimumab following recurrence on DC vaccination might result in improved clinical efficacy of ipilimumab. Furthermore, concurrent administration of DC vaccination and ipilimumab has been tested in two clinical studies, showing the suggestion of synergy with little added toxicity. Studies investigating whether DC vaccination potentiates PD-1 inhibition in the treatment of metastatic melanoma are currently ongoing.

In conclusion, ICI remains a viable treatment option for melanoma patients in case of recurrence on adjuvant DC vaccination. This adds to the notion that DC vaccination as an adjunct to ICI (either sequentially or concurrently) may have a role within the future treatment landscape of melanoma. Evidently, the therapeutic efficacy of adjuvant DC vaccination has to be proven, a phase III trial to that end is currently ongoing.

### Table 2. Clinical efficacy of immune checkpoint inhibition following dendritic cell vaccination.

| Treatment after progressive disease on ICI | PD-1 inhibition monotherapy after DC vaccination (n = 29) | Ipilimumab monotherapy after DC vaccination (n = 20) | Ipilimumab-nivolumab after DC vaccination (n = 8) |
|-------------------------------------------|----------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|
| **Response rate**                         | 15 (52%)                                                 | 7 (35%)                                           | 6 (75%)                                          |
| **Disease control rate**                  | 21 (72%)                                                 | 10 (50%)                                          | 6 (75%)                                          |
| **Best response on ICI**                 |                                                          |                                                   |                                                  |
| Complete response                          | 7 (24%)                                                  | 4 (20%)                                           | 2 (25%)                                          |
| Partial response                           | 8 (28%)                                                  | 3 (15%)                                           | 4 (50%)                                          |
| Stable disease                             | 6 (21%)                                                  | 3 (15%)                                           | 0                                                |
| Progressive disease                       | 8 (28%)                                                  | 10 (50%)                                          | 2 (25%)                                          |
| Median progression-free survival (months)  | 13.1                                                     | 3.9                                               | 5.6                                              |
| Median overall survival (months)          | 32.5                                                     | 30.0                                              | NR                                               |

*percentage of the number of patients with progressive disease, patients may have been treated with multiple agents after progressive disease on immune checkpoint inhibition.

Abbreviations: BRAF/MEKi, BRAF/MEK inhibition; BRAFi, BRAF inhibitor; DC, dendritic cell; ICI, immune checkpoint inhibition; NR, not reached.
Acknowledgments

The authors thank all patients for their interest and willingness to participate in the clinical trials. The authors thank Simone M. Hins-de Bree for clinical support, and the entire clinical and laboratory team involved in the performance of the trials.

Disclosure of potential conflicts of interest

AAMvdV received consultancy fees for participation in advisory boards of BMS, Ipsen, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi. JBAGH has provided consultation, attended advisory boards, and/or provided lectures for AIMM, Amgen, AZ, Bayer, BMS, Celsius Therapeutics, Gadeta, GSK, Immunocore, Ipsen, Merck Serono, MSD, Neogene therapeutics, Neon Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics and Vaximm, JBAGH received grant support from BMS, MSD, Neon Therapeutics and Novartis. JWBrG received consultancy fees for participation in advisory boards of BMS, MSD, Novartis, Pierre Fabre and Servier. MJBS received consultation fees for participation in advisory boards of Bristol-Myers Squibb, MSD and Pierre Fabre. RHK received personal grants and consultancy fees for participation in advisory boards of Astra Zeneca, BMS, MSD, Novartis and Pierre Fabre. RHTK participated in educational sessions of BMS and MSD. RHTK received grants from Roche. WRG received speakers’ fees from ESMO and MSD. WRG received consultancy fees for participation in advisory boards of BMS, IMS Health, IQVIA, Janssen-Cilag, MSD and Sanofi. WRG received research grants from Astellas, Bayer, Janssen-Cilag and Sanofi.

The other authors declare to have no disclosures.

Funding

This work was supported by The Dutch Cancer Society (KWF) under Grant KWO-2009-4402; IJMvdV is the recipient of NWO-Vici grant 016.140.655.

References

1. Gershenwald JE, Scolyer RA. Melanoma staging: American joint committee on cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105–2110. doi:10.1245/s10434-018-6513-7.
2. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob -J-J, et al. Ipilimumab plus
dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526. doi:10.1056/NEJMoa1104621.

3. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warcho E, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:10.1056/NEJMoa1412082.

4. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1271. doi:10.1056/NEJMoa1504030.

5. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlio MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;373(26):2521–2532. doi:10.1056/NEJMoa1503093.

6. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichmitzer M, Khattak A, Carlio MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi:10.1056/NEJMoa1802357.

7. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenkner M, Chiarion-Sileni V, Marquez-Rodas I, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–1835. doi:10.1056/NEJMoa1709030.

8. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–530. doi:10.1016/S1470-2045(15)70122-1.

9. Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823. doi:10.1056/NEJMoa1708539.

10. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszsay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615. doi:10.1016/S1470-2045(18)30142-6.

11. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszsay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–1876. doi:10.1056/NEJMoa1408868.

12. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. doi:10.1056/NEJMoa1406037.

13. Bol FK, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, et al. Natural human plasmacytoid dendritic cells induce robust tumor cell immunity in melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res. 2016;22(9):2155–2166. doi:10.1158/1078-0432.CCR-15-2205.

14. Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, Adema GI, Figdor CG, et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011;60(2):249–260. doi:10.1007/s00262-010-0942-x.

15. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Crookewit AJ, de Vries IJ, Boerman OC, Crookewit S, Oyen WJG, van Rossum MM, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma (EORTC 180180): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015;16(5):603–615. doi:10.1016/S1470-2045(15)70142-6.

16. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Crookewit S, Oyen WJG, van Rossum M, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res. 2013;73(3):1063–1075. doi:10.1158/0008-5472.CAN-12-2583.

17. de Vries IJ, Lesterhuis WJ, Scharenberg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Crookewit S, Britten CM, Torensma R, Adema GJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9(14):5091–5100.

18. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenberg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJM, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2010;16(20):5067–5078. doi:10.1158/1078-0432.CCR-10-1577.

19. Lesterhuis WJ, Schreibelt G, Scharenberg NM, Brouwer HM, Gerritsen MJ, Crookewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011;60(2):249–260. doi:10.1007/s00262-010-0942-x.
guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.

29. Schepmer M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346. doi:10.1016/0197-2456(96)00075-X.

30. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–681. doi:10.1016/S1470-2045(18)30139-6.

31. Larkin J, Ferucci P. Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma and elevated serum lactate dehydrogenase: a pooled analysis. Society for Melanoma Research 2016 Congress; 2016 Nov 6–9; Boston, MA.

32. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–1862. doi:10.1016/S0140-6736(17)31601-X.

33. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.

34. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummet R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.

35. Ochoa CE, Joseph RW. Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. Melanoma Manag. 2017;4(3):143–145. doi:10.2217/mmt-2017-0010.

36. Linette GP, Becker-Hapak M, Skidmore ZL, Barroja ML, Xu C, Hundal J, Spencer DH, Fu W, Cummins C, Robnett M, et al. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proc Natl Acad Sci U S A. 2019;116(47):23662–23670. doi:10.1073/pnas.1906026116.

37. Boudewijns S, Koorstra RH, Westdorp H, Schreibelt G, van den Eertwegh AJ, Geukes Poppen MH, Haanen JB, de Vries IJM, Figdor CG, Bol KF, et al. Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology. 2016;5(8):e1201625. doi:10.1080/2162402X.2016.1201625.

38. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009;15(19):6267–6276. doi:10.1158/1078-0432.CCR-09-1254.

39. Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Krustbog P, Thielemens K, Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330–1338. doi:10.1200/JCO.2015.63.4121.

40. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, van de Rakt M, Lesterhuis WJ, van Riel M, Punt CJA. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res. 2013;19(6):1525–1533. doi:10.1158/1078-0432.CCR-12-1879.